FDA panel weighs access to 7 unapproved injectable peptides

A Food and Drug Administration advisory panel began a two-day meeting Thursday to review whether compounding pharmacies should be allowed to make seven popular injectable peptides, including BPC-157, TB-500 and MOTs-C. The compounds are widely marketed in the wellness industry for uses such as injury recovery, muscle growth, fat loss and wound healing, but none has completed the large clinical trials required for FDA approval. FDA scientists recommended against allowing compounded versions, arguing the available research is limited and relies heavily on animal data. The debate has drawn added attention because Health Secretary Robert F. Kennedy Jr. has backed easing peptide restrictions, while the agency recently reshaped the advisory committee and added temporary voting members.